comprehensive -WSS

comprehensive

author：explore 2025-09-14 21:55:01 - browse：87

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Gain of function research would be limited under House proposal

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

focus

comprehensive

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Kaiser's Risant Health gobbled up Geisinger. Who is next?

How to save PrEP access — and even expand it

Shifting the focus from loneliness to social health

Continuity nursing helped my family in our darkest PICU moments

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Trump demands the U.S. pay no more for drugs than other countries … again

Anthos stroke drug appears safer than common blood thinner

Affirmative action in medical school literally saved lives

BMI, flaws aside, is found to be useful estimate of body fat in youth

focus

World's first CRISPR

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Ultragenyx gene therapy for rare liver ailment succeeds in late

Innovation in antibiotics is ailing. 'Brain drain' may kill it

PBM reforms clear House panel

Change Healthcare can notify patients about the breach, HHS says

hotspot

hotspot

knowledge

focus